TY - JOUR
KW - Humans
KW - *Muscarinic Antagonists
KW - *Pulmonary Disease, Chronic Obstructive
KW - Retrospective Studies
KW - Adrenergic beta-2 Receptor Agonists
KW - Nebulizers and Vaporizers
KW - Drug Combinations
KW - Administration, Inhalation
KW - Patient Acceptance of Health Care
KW - Primary health care
KW - Bronchodilator Agents
KW - Adrenal Cortex Hormones
KW - Copd
KW - clinical outcomes
KW - primary care setting
KW - single-inhaler LAMA/LABA dual therapy
KW - treatment patterns
AU - G. Requena
AU - V. Banks
AU - A. Czira
AU - R. Wood
AU - T. Tritton
AU - R. Wild
AU - C. Compton
AU - A. Ismaila
AD - Value Evidence and Outcomes, GSK, R&D Global Medical, Brentford, Middlesex, UK.
Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
AN - 36908830
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC9997204
DO - 10.2147/copd.s389281
DP - NLM
ET - 2023/03/14
LA - eng
N1 - 1178-2005
Requena, Gema
Orcid: 0000-0002-1889-6656
Banks, Victoria
Orcid: 0000-0002-0087-7641
Czira, Alexandrosz
Orcid: 0000-0002-3395-6186
Wood, Robert
Orcid: 0000-0002-6977-435x
Tritton, Theo
Wild, Rosie
Orcid: 0000-0002-9963-6441
Compton, Chris
Orcid: 0000-0002-7564-5343
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Journal Article
New Zealand
Int J Chron Obstruct Pulmon Dis. 2023 Mar 5;18:231-245. doi: 10.2147/COPD.S389281. eCollection 2023.
PY - 2023
SN - 1176-9106 (Print)1176-9106
SP - 231
EP - 245
T2 - Int J Chron Obstruct Pulmon Dis
TI - Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
VL - 18
ER -